Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients
- 49 Downloads
- 12 Citations
Abstract
The efficacy and safety of a combination of ganciclovir plus GM-CSF was evaluated in AIDS patients with cytomegalovirus retinitis. In phase A, patients were randomized to receive ganciclovir, 5 mg/kg every 12 h for 14 days followed by 5 mg/kg daily, with (n=24) or without (n=29) GM-CSF (1–8 µg/kg daily subcutaneously) to maintain absolute neutrophil counts between 2500 and 5000 cells/µl. In phase B, after 16 weeks zidovudine was added to the regimen of 16 patients receiving ganciclovir plus GM-CSF and 20 receiving ganciclovir alone. At this stage, GM-CSF was added to the treatment protocol of any patient receiving ganciclovir plus zidovudine who became neutropenic. In phase A, patients in the ganciclovir plus GM-CSF group had significantly higher neutrophil counts than ganciclovir-alone patients (p=0.0001). Overall, 12.5 % of patients treated with GM-CSF developed neutropenia (absolute neutrophil counts<500/µl phase A and<750/µl phase B) compared with 45 % of patients treated without GM-CSF. GM-CSF patients missed 10 of a possible 4705 scheduled doses of ganciclovir compared with 34 missed doses of a possible 6584 in the ganciclovir-alone group (p=0.011). There was a trend, although not statistically significant, for patients in the GM-CSF group to experience delayed progression of their retinitis. There was no consistent evidence that GM-CSF stimulated the proliferation of cytomegalovirus or human immunodeficiency virus in the GM-CSF group compared with patients receiving ganciclovir alone. The addition of GM-CSF to standard ganciclovir therapy for the treatment of cytomegalovirus retinitis reduced the haematological toxicity of the antiviral drug and allowed closer adherence to the dosage schedule. In addition, patients were able to receive concomittant zidovudine therapy.
Keywords
Human Immunodeficiency Virus Neutropenia Zidovudine Neutrophil Count GanciclovirReferences
- 1.Mintz L, Drew WI, Miner RC, Braff EH Cytomegalovirus infections in homosexual men: an epidemiologic study. Annals of Internal Medicine 1983, 98: 326–329.Google Scholar
- 2.Holland GN, Pepose JS, Pettit TH, Gottlieb MS, Yee RD, Foos RY Acquired immune deficiency syndrome. Ocular manifestations. Ophthalmology 1983, 90: 859–873.PubMedGoogle Scholar
- 3.USP DI: Drug information for the health-care profession. 11th Edition, Volumes IA and IB. The United States Pharmacopea Convention, 1991.Google Scholar
- 4.Hochster H, Dietrich D, Bozzette S, Reichman RC, Connor JD, Liebes L, Sonke RL, Spector SA, Valentine F, Pettinelli C, Richman DD Toxicity of combined ganciclovir and zidovudine for cytomegalovirus associated with AIDS. Annals of Internal Medicine 1990, 113: 111–117.PubMedGoogle Scholar
- 5.Millar AB, Miller RF, Patou G, Mindel A, Marsh R, Semple SJG Treatment of cytomegalovirus retinitis with zidovudine and ganciclovir in patients with AIDS: outcome and toxicity. Genitourinary Medicine 1990, 66: 156–158.PubMedGoogle Scholar
- 6.Vadas A, Nicola NA, Metcalf D Activation of antibody-dependent cell-mediated cytotoxicity of human neutrophils and eosinophils by separate colony-stimulating factors. Journal of Immunology 1983, 130: 795–759.Google Scholar
- 7.Metcalf D, Begley CG, Johnson GR, Nicola NA, Vadas MA, Lopez AF, Williamson DJ, Wong GG, Clark SC, Wang EA Biological properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1986, 67: 37–45.PubMedGoogle Scholar
- 8.Gerhartz HH, Engelhard M, Meusers P, Brittinger G, Wilmanns W, Schlimok G, et al. Randomized, double blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 1993, 82: 2329–2339.PubMedGoogle Scholar
- 9.Neumanitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM, Freedman AS, Onett N, Gillis S, Oette D, Gold M, Bruckner CD, Hansen JA, Ritz J, Appelbaum FR, Armitage JO, Nadler LM Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. New England Journal of Medicine 1991, 324: 1773–1778.PubMedGoogle Scholar
- 10.Groopman JE, Mitsuyasu RT, Deleo MJ, Oette DH, Golde DW Effect of recombinant human granulocyte-macrophage colony stimulating factor on myelopoiesis in acquired immune deficiency syndrome. New England Journal of Medicine 1987, 317: 593–598.PubMedGoogle Scholar
- 11.Hardy WD Combined ganciclovir and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. Journal of Acquired Immune Deficiency Syndromes 1991, 4, Supplement 1: 22–28.Google Scholar
- 12.Jabs DA, Green WR, Fox R, Polk BF, Bartlett JG Ocular manifestations of acquired immune deficiency syndrome. Ophthalmology 1989, 96: 1092–1099.PubMedGoogle Scholar
- 13.Grossberg HS, Bonnem EM, Buhles WC GM-CSF with ganciclovir for the treatment of CMV retinitis in AIDS. New England Journal of Medicine 1989, 320: 1560.Google Scholar
- 14.Pluda JM, Yarchoan R, Smith PD, McAtee N, Shay LE, Oette D, Maha M, Wahl SM, Myers CE, Broder S Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe immunodeficiency virus infection. Blood 1990, 76: 463–472.PubMedGoogle Scholar
- 15.Kaplan LD, Kahn JO, Crowe S, Northfelt D, Neville P, Grossberg H, Abrams DI, Tracey J, Mills J, Volberding PA Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. Journal of Clinical Oncology 1991, 9: 929–940.PubMedGoogle Scholar
- 16.Scadden DT, Bering HA, Levine JD, Bresnahan J, Evans L, Epstein C, Groopman JE Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon-alpha and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma. Journal of Clinical Oncology 1991, 9: 802–808.PubMedGoogle Scholar
- 17.Levine JD, Allan JD, Tessitore JH, Falcone N, Galasso F, Israel RJ, Groopman JE Recombinant human granulocyte-macrophage colony-stimulating factor ameliorates zidovudine-induced neutropenia in patients with acquired immunodeficiency syndrome (AIDS)/AIDS-related complex. Blood 1991, 78: 3148–3154.PubMedGoogle Scholar
- 18.Davey RT, Davey VJ, Metcalf JA, Zurlo JJ, Kovacs Ja, Falloon J, Polis MA, Zunich KM, Masur H, Lane HC A phase I/II trial of zidovudine and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection. Journal of Infectious Diseases 1991, 64: 43–52.Google Scholar
- 19.Gill PS, Bernstein-Singer M, Espina BM, Rarick M, Magy F, Montgomery T, Berry MS, Levine A Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi's sarcoma. AIDS 1992, 6: 1477–1481.PubMedGoogle Scholar
- 20.Krown SE, Paredes J, Bundow D, Polsky B, Gold JWM, Flomenberg N Interferon-α, zidovudine, and granulocyte-macrophage colony-stimulating factor: a phase I AIDS Clinical Trials Group study in patients with Kaposi's sarcoma associated with AIDS. Journal of Clinical Oncology 1992, 10: 1344–1351.PubMedGoogle Scholar
- 21.Perno CF, Yarchoan R, Cooney DA, Hartman NR, Webb DSA, Hao Z, Mitsuya H, Johns DG, Broder S Replication of human immunodeficiency virus in monocytes, granulocyte/macrophage colony-stimulating factor potentiates viral production yet enhances the antiviral effect mediated by 3′azido-2′3′-dideoxythymidine and other dideoxynucleoside congeners of thymidine. Journal of Experimental Medicine 1989, 169: 933–951.CrossRefPubMedGoogle Scholar